It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The relationship of SARS-CoV-2 pulmonary infection and severity of disease is not fully understood. Here we show analysis of autopsy specimens from 24 patients who succumbed to SARS-CoV-2 infection using a combination of different RNA and protein analytical platforms to characterize inter-patient and intra-patient heterogeneity of pulmonary virus infection. There is a spectrum of high and low virus cases associated with duration of disease. High viral cases have high activation of interferon pathway genes and a predominant M1-like macrophage infiltrate. Low viral cases are more heterogeneous likely reflecting inherent patient differences in the evolution of host response, but there is consistent indication of pulmonary epithelial cell recovery based on napsin A immunohistochemistry and RNA expression of surfactant and mucin genes. Using a digital spatial profiling platform, we find the virus corresponds to distinct spatial expression of interferon response genes demonstrating the intra-pulmonary heterogeneity of SARS-CoV-2 infection.
Understanding the pathology in the lungs of patients with COVID-19 might provide clues as to the susceptibility of patients and how the SARS-CoV-2 virus can be fatal. Here the authors analyze cadaveric pulmonary tissue and show one group with high viral load, early death, inflammation and inflammatory damage, and another with low viral load, longer duration of disease, and more M2-like polarization and fibrotic lung damage.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
2 Massachusetts General Hospital, Department of Pathology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
3 Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts General Hospital, Department of Pathology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
4 Memorial Sloan Kettering Cancer Center, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)
5 Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); The Broad Institute, Cambridge, USA (GRID:grid.66859.34)
6 The Broad Institute, Cambridge, USA (GRID:grid.66859.34)
7 Massachusetts General Hospital, Department of Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
8 Advanced Cell Diagnostics, a Bio-Techne Brand, Newark, USA (GRID:grid.417415.2)
9 NanoString Inc., Seattle, USA (GRID:grid.417415.2)
10 Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); The Broad Institute, Cambridge, USA (GRID:grid.66859.34); Massachusetts General Hospital, Department of Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
11 Columbia University Irving Medical Center, Department of Pathology and Cell Biology, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
12 Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts General Hospital, Department of Pathology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); The Broad Institute, Cambridge, USA (GRID:grid.66859.34)
13 Brigham and Woman’s Hospital, Department of Pathology, Boston, USA (GRID:grid.66859.34)
14 Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts General Hospital, Department of Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)